Evidence map›Paper›PMID 26010541›Full record

ArticlePloS one2015

Cambinol, a novel inhibitor of neutral sphingomyelinase 2 shows neuroprotective properties.

Mariana Figuera-Losada, Marigo Stathis, Joelle M Dorskind, Ajit G Thomas, Veera Venkata Ratnam Bandaru, Seung-Wan Yoo, Nicholas J Westwood, Graeme W Rogers, Justin C McArthur, Norman J Haughey and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 95 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. A novel approach to combatMicrobiology spectrum · 2026
    Article
  6. Review
  7. Neutral sphingomyelinase 2: A promising drug target for CNS disease.Advances in pharmacology (San Diego, Calif.) · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Mariana Figuera-LosadaBrain Science Institute Drug Discovery Program, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Marigo StathisBrain Science Institute Drug Discovery Program, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Joelle M DorskindDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Ajit G ThomasBrain Science Institute Drug Discovery Program, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Veera Venkata Ratnam BandaruDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Seung-Wan YooDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Nicholas J WestwoodSchool of Chemistry and Biomedical Sciences Research Centre, University of Saint Andrews and EaStCHEM, North Haugh, Saint Andrews, Fife, KY16 9ST, United Kingdom.
Graeme W RogersSchool of Chemistry and Biomedical Sciences Research Centre, University of Saint Andrews and EaStCHEM, North Haugh, Saint Andrews, Fife, KY16 9ST, United Kingdom.
Justin C McArthurDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Norman J HaugheyDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Richard T. Johnson Division of Neuroimmunology and Neurological Infections, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Barbara S SlusherBrain Science Institute Drug Discovery Program, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Camilo RojasBrain Science Institute Drug Discovery Program, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Johns Hopkins University · USJohns Hopkins Medicine · USUniversity of St Andrews · GB

Funding

Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
Therapeutic CoreP30MH075673 · NIMH · JOHNS HOPKINS UNIVERSITY · PI Leah Helane Rubin · 2006 to 2026
$33.2M
Surrogate Marker CoreP01MH105280 · NIMH · JOHNS HOPKINS UNIVERSITY · PI SACKTOR, NED C · 2015 to 2019
$6.5M
Mechanisms of Neuroinflammation in HANDR01MH077542 · NIMH · JOHNS HOPKINS UNIVERSITY · PI HAUGHEY, NORMAN J · 2007 to 2016
$3.4M
Altered Amyloid Processing HIVR01MH096636 · NIMH · JOHNS HOPKINS UNIVERSITY · PI HAUGHEY, NORMAN J · 2013 to 2017
$2.0M
Dysregualtion of gliotransmission in models of neuroHIVR01MH110246 · NIMH · JOHNS HOPKINS UNIVERSITY · PI HAUGHEY, NORMAN J · 2016 to 2020
$2.0M
Combinational Systems Analyses to Identify Neural Circuits Perturbed by HIVR03MH103985 · NIMH · JOHNS HOPKINS UNIVERSITY · PI HAUGHEY, NORMAN J · 2014 to 2015
$162k
NCATS NIH HHS UL1 TR001079NIMH NIH HHS P01 MH105280NIMH NIH HHS P30 MH075673NIMH NIH HHS P30 MH075673-06NIMH NIH HHS R01 MH077542NIMH NIH HHS R01 MH096636NIMH NIH HHS R01 MH110246NIMH NIH HHS R03 MH103985
6 · The paper itself

Abstract

Ceramide is a bioactive lipid that plays an important role in stress responses leading to apoptosis, cell growth arrest and differentiation. Ceramide production is due in part to sphingomyelin hydrolysis by sphingomyelinases. In brain, neutral sphingomyelinase 2 (nSMase2) is expressed in neurons and increases in its activity and expression have been associated with pro-inflammatory conditions observed in Alzheimer's disease, multiple sclerosis and human immunodeficiency virus (HIV-1) patients. Increased nSMase2 activity translates into higher ceramide levels and neuronal cell death, which can be prevented by chemical or genetic inhibition of nSMase2 activity or expression. However, to date, there are no soluble, specific and potent small molecule inhibitor tool compounds for in vivo studies or as a starting point for medicinal chemistry optimization. Moreover, the majority of the known inhibitors were identified using bacterial, bovine or rat nSMase2. In an attempt to identify new inhibitor scaffolds, two activity assays were optimized as screening platform using the recombinant human enzyme. First, active hits were identified using a fluorescence-based high throughput compatible assay. Then, hits were confirmed using a 14C sphingomyelin-based direct activity assay. Pharmacologically active compounds and approved drugs were screened using this strategy which led to the identification of cambinol as a novel uncompetitive nSMase2 inhibitor (Ki = 7 μM). The inhibitory activity of cambinol for nSMase2 was approximately 10-fold more potent than for its previously known target, silence information regulator 1 and 2 (SIRT1/2). Cambinol decreased tumor necrosis factor-α or interleukin-1 β-induced increases of ceramide and cell death in primary neurons. A preliminary study of cambinol structure and activity allowed the identification of the main structural features required for nSMase2 inhibition. Cambinol and its analogs may be useful as nSMase2 inhibitor tool compounds to prevent ceramide-dependent neurodegeneration.

Indexed as

AnimalsCattleCell DeathCell SurvivalCeramidesCytokinesDendritesDrug Evaluation, PreclinicalEnzyme AssaysEnzyme InhibitorsFluorescenceHEK293 CellsHippocampusHumansInterleukin-1betaNaphthalenescambinolCeramidesCytokinesEnzyme InhibitorsInterleukin-1betaNaphthalenesNeuroprotective AgentsPyrimidinonesRecombinant ProteinsSphingomyelin PhosphodiesteraseTumor Necrosis Factor-alpha

Identifiers

PMID26010541
PMCPMC4444023
OpenAlexW1511544167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.